---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117727"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:46:10.180767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q3 revenue $108.8M (+64% YoY), net income $4.2M; FY guidance reaffirmed

## Summary
- Total revenue $108.8M, up 64% from $66.4M in Q3 2023.
- Net income $4.2M ($0.12 diluted EPS) vs net loss of $25.4M in prior year.
- Gross margin 56% vs 61% a year ago due to shift to service revenue.
- FY 2024 revenue guidance reaffirmed at $425M–$445M (76–84% growth).
- Cash $330.1M as of Sep 30; owned 18 aircraft for the National OCS Program.

## SEC filing metadata
- accession: 0000950170-24-117727
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017024117727/0000950170-24-117727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017024117727/tmdx-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117727
- JSON: https://secwatch.observer/filing/0000950170-24-117727.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.